Erin Wilson
Stock Analyst at Morgan Stanley
(1.76)
# 3,337
Out of 5,154 analysts
23
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $28 → $22 | $7.04 | +212.50% | 8 | Sep 2, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $175.60 | +316.86% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $181.32 | +112.33% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $178.50 | +48.46% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $469.38 | -56.33% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $110.60 | +126.04% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $23.92 | +58.86% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $14.25 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $518.84 | -34.28% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $0.85 | +6,249.95% | 4 | Nov 14, 2017 |
Rapid7
Sep 2, 2025
Maintains: Equal-Weight
Price Target: $28 → $22
Current: $7.04
Upside: +212.50%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $175.60
Upside: +316.86%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $181.32
Upside: +112.33%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $178.50
Upside: +48.46%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $469.38
Upside: -56.33%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $110.60
Upside: +126.04%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $23.92
Upside: +58.86%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $14.25
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $518.84
Upside: -34.28%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $0.85
Upside: +6,249.95%